Related by context. All words. (Click for frequent words.) 74 Disease Activity 70 DAS# CRP 69 Health Assessment Questionnaire 69 SELENA SLEDAI 68 Brief Psychiatric 68 Crohn Disease Activity 67 DAS# [002] 67 NIH CPSI 66 WOMAC 66 Severity Index PASI 65 Ocular Surface Disease 65 Index CDAI 65 Fibromyalgia Impact Questionnaire 65 Psoriasis Area 65 Pain Intensity 65 WOMAC pain 65 Inventory BPI 64 Functional Assessment 64 Montgomery Åsberg Depression 64 Lower Limb 64 Score DAS# 64 Visual Analogue Scale VAS 64 CDAI 64 Ejection Fraction 64 PsA 64 Natalizumab 63 subscores 63 Scale EDSS 63 Visual Analog Scale 63 plus methotrexate 63 non menstrual pelvic 63 Brief Pain 63 Main Outcome Measures 62 Visual Analog 62 Expanded Disability Status 62 serologically active patients 62 nasal symptom 62 Alzheimer Disease Assessment 62 Relapsing Multiple Sclerosis 62 bronchial hyperresponsiveness 62 UPDRS 62 subscore 62 Knee Osteoarthritis 62 Myocardial 62 UPDRS motor 62 Fracture Risk 62 Rating Scale MADRS 62 NIS LL 62 Ischemic 62 Score IPSS 62 pain subscale 62 Atopic Dermatitis 62 SGRQ 62 symptom severity 61 albumin excretion rate 61 Visual Analogue Scale 61 Global Impression CGI 61 erythrocyte sedimentation rate 61 Claudication 61 Montgomery Asberg Depression 61 subscale scores 61 Status Scale EDSS 61 PANSS 61 ADCS CGIC 61 abdominal pain abdominal discomfort 61 YMRS 61 subscales 61 Symptom Score 61 left ventricular diastolic 61 PCWP 61 International Prostate Symptom 61 EQ 5D 61 Histologic 61 hip BMD 60 Postoperatively 60 Erythema 60 Dyspnea 60 Relapsing Remitting Multiple Sclerosis 60 Danazol 60 pulmonary arterial 60 NYHA functional class 60 lumbar spine BMD 60 Outcome Measures 60 4mg/kg 60 Physical Function 60 flow mediated dilation 60 vitreous floaters 60 liver histology 60 tipranavir r 60 Unified Parkinson Disease 60 Scale PANSS 60 HRQOL 60 SF #v# 60 8mg/kg 60 hematologic parameters 60 FACIT Fatigue 60 Subclinical 60 Secondary endpoints include 60 hematological parameters 60 Secondary endpoints included 60 Ankylosing Spondylitis 60 nausea photophobia 60 aspartate aminotransferase AST 60 NMIBC 60 clinically meaningful improvement 60 dyspnoea 60 HAQ DI 60 Antitumor 60 Primary endpoints 60 HAMD 60 HDRS 60 MADRS score 60 CIMZIA TM certolizumab pegol 60 HAM D# 60 lumbar spine bone 60 AST ALT 60 Negative Syndrome 60 QoL 60 Clinical Relevance 60 Electrical Stimulation 60 Rating Scale UPDRS 59 Distress Scale 59 C Reactive Protein 59 Patients Receiving 59 alanine aminotransferase ALT 59 methotrexate monotherapy 59 urinary albumin 59 ADAS Cog 59 SGOT 59 Negative Symptoms 59 function subscales 59 intraabdominal 59 % Confidence Interval 59 Scale EDSS score 59 fluticasone salmeterol 59 Clinical Outcome 59 CIMZIA ™ 59 NIHSS 59 Decitabine 59 oxycodone CR 59 akinesia 59 SGPT 59 CIMZIA TM 59 See CLINICAL PHARMACOLOGY 59 Main Outcome Measure 59 Endothelial function 59 CORE OM 59 MCyR 59 CDAI score 59 Severity Index 59 IBDQ 59 Rheumatoid Arthritis Patients 59 WOMAC scores 59 extraocular 59 mcg QD 59 Predict Risk 59 aspartate aminotransferase 59 F FDG PET 59 Chronic Illness Therapy 59 ADCS ADL 59 Watchful Waiting 59 desvenlafaxine succinate 59 Chronic Sinusitis 59 ACE Inhibitors 59 Severity MSCS score 59 moderate renal impairment 59 orthostatic 59 Severe Asthma 59 interobserver 59 Chronic Prostatitis 59 mineral density BMD 59 submaximal 59 PANSS total 59 antithymocyte globulin 59 Rating Scale BPRS 59 Rheumatoid 59 Partial Response 59 Metastatic Renal Cell Carcinoma 59 cough dyspnea 59 Left Ventricular 59 constipation predominant IBS 59 Index WOMAC 59 Oral Fingolimod 59 mg TID 58 Skin sterol 58 Beta Blockers 58 Treated Patients 58 Meta Analysis 58 tibiofemoral 58 ECOG PS 58 conjunctival hyperemia 58 enthesitis 58 Juvenile Idiopathic Arthritis 58 ecchymosis 58 Adjuvant Treatment 58 salmeterol fluticasone 58 acromegalic patients 58 Assessment Questionnaire 58 hepatic enzymes 58 neuritic 58 nonvertebral 58 chills fever headache 58 ADAS cog 58 RECIST Response Evaluation Criteria 58 detrusor 58 Generalized Anxiety Disorder 58 atrophic gastritis 58 mucosal healing 58 Beck Anxiety Inventory 58 HADS 58 Thrombolysis 58 ACR# response 58 Atomoxetine 58 IRLS score 58 mucosal inflammation 58 Score TOS 58 paresthesias 58 Prognostic 58 Cardiotoxicity 58 HRQoL 58 EDSS score 58 Cimzia ® certolizumab pegol 58 DAS# scores 58 Respiratory Symptoms 58 tolterodine ER 58 PASI scores 58 BMI z 58 Rheumatoid Arthritis RA 58 moderate hepatic impairment 58 Non Responders 58 function subscale 58 T2DM 58 anemia hemoglobin 58 rhinorrhea 58 Erosive Esophagitis 58 headache abdominal pain 58 Secondary endpoints 58 alanine aminotransferase 58 acetabular dysplasia 58 vasomotor 58 radiographic progression 58 clinically meaningful reductions 58 Improves Outcomes 58 Platinol ® 58 hyperreflexia 58 premorbid 58 glycaemia 58 Neuropsychiatric Inventory NPI 58 nausea somnolence 58 lactate dehydrogenase 58 neutropaenia 58 BILAG 58 postop 58 haematologic 58 Autologous Stem Cell Transplantation 58 Scale Cognitive Subscale 58 demonstrated clinically meaningful 58 TNF Tumor Necrosis Factor 58 ‰ ¥ 58 total cholesterol triglycerides 58 Depressive Symptoms 58 QIDS SR 58 parkinsonian 58 Histological 58 semiquantitative 58 Prolongs Survival 58 pT2 58 tumor necrosis 58 erection hardness 58 FOLFOX6 58 reflux esophagitis 57 mg BID dose 57 Peripheral Arterial 57 MADRS 57 Symptom Scale 57 Endocrine Therapy 57 Quantitation 57 IOP lowering 57 Gonadotropin 57 Lower Extremity 57 phonophobia 57 Cognitive Function 57 TLUS 57 Solid Tumors criteria 57 ALS Functional 57 Alkaline Phosphatase 57 serum urate 57 serum cortisol 57 Invasive Fungal Infections 57 Symptom 57 Lumbar spine 57 highly emetogenic 57 urothelial carcinoma 57 Stomatitis 57 Acute Physiology 57 Placebo Controlled Trial 57 adjunctive placebo 57 salivary flow 57 IPSS 57 NNT = 57 â ‰ ¥ 57 Hypercholesterolemia 57 DLQI 57 visceral adiposity 57 Secondary efficacy endpoints 57 #mg/day [001] 57 somatostatin analog 57 serum testosterone 57 Thromboembolic 57 calculated creatinine clearance 57 Histopathologic 57 bleeding pallor 57 zonisamide SR 57 relapsed MM 57 lopinavir r arm 57 Chronic Renal Failure 57 % CI #.#-#.# [003] 57 Ashworth Scale 57 tissue oxygenation 57 achieved ACR# 57 Symptom Severity 57 Prospective Randomized 57 Chemotherapy induced 57 Ischaemic 57 Metastatic Prostate Cancer 57 clinically meaningful improvements 57 EORTC QLQ C# 57 morphometric vertebral fractures 57 Ishak fibrosis score 57 CI -#.# 57 Oswestry Disability Index 57 Apidra ® 57 Nebulized 57 APTIVUS r 57 radicular 57 Oesophageal 57 Symptom severity 57 immunostaining 57 Is Well Tolerated 57 PEG IFN 57 rheumatoid factor 57 iPTH 57 Abnormal Involuntary Movement 57 Prognostic significance 57 Hepatic Encephalopathy 57 hepatic lesions 57 Brain Metastases 57 Elastography 57 esophageal carcinoma 57 histologically proven 57 Bone Mineral Density 57 lymphocyte count 57 Flu Cy 57 Immune Responses 57 % CI #.#-#.# [008] 57 hemoglobin Hb 57 autonomic dysfunction 57 #q# deletion syndrome 57 intra articular injection 57 serum PTH 57 bronchoalveolar lavage 57 STRIDE PD 57 Pegylated Liposomal Doxorubicin 57 HOMA IR 57 dimensional echocardiography 57 hours postdose 57 p ≤ 57 B Cell Lymphoma 57 FDG uptake 57 Patients Treated With 57 Endothelial Function 57 dyslipidaemia 57 Allergic Rhinitis 57 GH deficiency 57 Showed Significant 57 HRQL 57 elevated ALT 57 diabetes dyslipidemia 57 morphologic characteristics 57 infraspinatus 57 Secondary Hyperparathyroidism 57 intratumoral 57 Demonstrated Significant 57 KOOS 57 PEGylated anti 57 Comorbidity 57 OSDI 57 WOMAC TM 57 moderately emetogenic 57 Scale cognitive subscale 57 Ischemic Stroke 57 Lowers Risk 57 Long Term Efficacy 57 cinacalcet 57 -#.# ± [002] 57 left ventricular LV 57 Bioavailability 57 hyperhomocysteinemia 57 Symptom Relief 57 CLINICAL PHARMACOLOGY 57 transaminase elevations 57 Double Blind Randomized 57 TMC# r 57 pT3 57 RAPAFLO R 57 Kidney Function 57 Proteinuria 56 Solid Tumors 56 serum HBV DNA 56 Cardiorespiratory fitness 56 Prophylactic Treatment 56 interobserver agreement 56 dermal collagen 56 Peginterferon Alfa 2a 56 DAS# remission 56 Angioedema 56 radiotherapy RT 56 pericardial effusion 56 TNFalpha 56 Leukemias 56 Orthostatic Hypotension 56 eNO 56 Prostatic 56 posttreatment 56 depressive symptomatology 56 Squamous Cell Carcinoma 56 HDL Cholesterol 56 Pelvic Organ Prolapse 56 Mean Symptom Complex 56 Nonalcoholic Fatty Liver Disease 56 Fecal Incontinence 56 ACE Inhibitor 56 Elderly Patients 56 Adjunctive 56 lowest tertile 56 Differential Diagnosis 56 P = .# 56 Hemolysis 56 Lubiprostone 56 macroalbuminuria 56 Sleep Disturbances 56 TRAIL R1 56 salmeterol fluticasone propionate 56 Pharmacodynamics 56 Adalimumab 56 Liver Failure 56 adenotonsillectomy 56 hypophosphatemia 56 Renal Function 56 Febrile 56 unfractionated heparin UFH 56 hallux rigidus 56 IIEF 56 arterial oxygen saturation 56 Heart Failure Patients 56 myoclonus 56 TNF receptor 56 Pharmacokinetics PK 56 Spasticity 56 glycosylated hemoglobin HbA1c 56 Systemic Sclerosis 56 antibody titer 56 Fulvestrant 56 Thrombotic 56 Dysmenorrhea 56 Postoperative 56 Hormone Refractory Prostate Cancer 56 Tiotropium 56 Neuropathic 56 rFSH 56 Hospitalized Patients 56 abdominal adiposity 56 T2 lesion volume 56 Cystatin C 56 Hematologic 56 PANSS scores 56 radiographically 56 International Prognostic Scoring 56 INVEGA ® 56 Benign Prostatic Hyperplasia 56 scores TNSS 56 GI motility 56 achieved statistical significance 56 knee osteoarthritis OA 56 Somnolence 56 Apolipoprotein B 56 exploratory endpoints 56 mg BID 56 serum phosphate 56 Uterine 56 multivariable adjusted 56 Inflammatory Pain 56 Cystectomy 56 Chemotherapy Induced 56 anthropometric measures 56 Ankle Brachial Index 56 vastus lateralis 56 Alanine 56 Functional Outcomes 56 artery elasticity 56 mcg BID 56 affective psychosis 56 p = NS 56 comorbid anxiety 56 Radiation Induced 56 fatigability 56 postinjury 56 ACTEMRA TM 56 EUFLEXXA R 56 poststroke 56 Demonstrates Efficacy 56 Hemodynamic 56 endometrial thickness 56 3mg/kg 56 ALT elevations 56 intact parathyroid hormone 56 metabolic parameters 56 flutamide 56 dactylitis 56 mg/m2 dose 56 experimental allergic encephalomyelitis 56 Tasigna prolongs 56 Tumor Response 56 myeloperoxidase 56 femoral neck BMD 56 colorectal adenoma 56 Pharmacologic 56 Am Soc Nephrol 56 Retreatment 56 urinary N telopeptide 56 Therapy Reduces 56 Pharmacodynamic 56 IL 1ß 56 psychosocial functioning 56 timepoints 56 hepatic cirrhosis 56 creatine kinase 56 Immunosuppressant 56 Hypertrophy 56 #mg/day [002] 56 HBeAg 56 unresectable HCC 56 euthymic patients 56 Immunogenicity 56 glomerular filtration 56 fasting plasma 56 quantitative computed tomography 56 -#.# mg dL [001] 56 IELT 56 Helicobacter pylori eradication 56 MoxDuo TM IR 56 Posaconazole 56 euthymic 56 extrapyramidal symptoms 56 McGill Pain Questionnaire 56 pharmacodynamic parameters 56 creatinine ratio 56 Symptom Checklist 56 Follicular Lymphoma 56 elevated IOP 56 neutropenia thrombocytopenia 56 CSBM 56 prucalopride 56 dysuria 56 oral levofloxacin 56 Single Dose 56 abnormal ejaculation 56 Abdominal Pain 56 nasopharyngitis headache 56 HRCT 56 pulmonary capillary wedge 56 hyperarousal 56 chemoradiation therapy 56 Demonstrate Significant 56 Thymic 56 serum IgG 56 Treatment Outcome 56 gadolinium enhancing 56 plasma cortisol 56 Assessment Scale 56 Chronic Pelvic Pain 56 fasting plasma glucose 56 nicardipine 56 cardio respiratory fitness 56 spontaneous bowel movements 56 mRS 56 Significantly Improved 56 serum IGF 56 baseline LDH 56 induration 56 nerve conduction velocity 56 Dilatation 56 metastatic malignant 56 Creatinine 56 Unfractionated Heparin 56 CC genotype 56 Cardiovascular Disease Risk 56 systemic corticosteroid 56 Response Evaluation Criteria 56 gadolinium enhanced 56 interleukin IL -6 56 leukocyte counts 55 CIMZIA R 55 prospectively stratified 55 serum urate levels 55 Platelet Aggregation 55 Hepatitis C Genotype 55 oesophagitis 55 Moxifloxacin 55 % CI #.#-#.# [007] 55 ankle dorsiflexion 55 Immunomodulatory 55 viral titers 55 hyperalgesia 55 comorbid depression 55 bioavailable testosterone 55 mineral density 55 PLMs 55 lumbosacral spine 55 mg QD 55 Disease Progression 55 ACR Pedi 55 bladder carcinoma 55 PaO 2 55 lipid elevations 55 SBM frequency 55 thetreatment 55 Treating Chronic 55 Uric Acid 55 mTSS 55 cEVR 55 tapentadol ER 55 parasitemia 55 varus deformity 55 aminotransferases 55 dyssynchrony 55 denervation 55 corticosteroid dose 55 Systolic Blood Pressure 55 Growth Hormone Deficiency 55 sub maximal 55 Castration Resistant Prostate Cancer 55 Non Alcoholic Fatty 55 APACHE II 55 Protease Inhibitors 55 estramustine 55 Albuminuria 55 hepatic fibrosis 55 Patients Suffering 55 Cerebellar 55 Serum concentrations 55 Catheter Associated 55 anterior uveitis 55 CCyR 55 aminotransferase 55 gastro esophageal reflux 55 EDSS scores 55 leukocyte count 55 hypovitaminosis D 55 plasma renin activity 55 FDG-PET/CT 55 Aortic Stenosis 55 Beta Amyloid 55 Pioglitazone 55 Pain Rating Scale 55 Suboptimal 55 Decompensated Heart Failure 55 guanfacine extended release 55 IRLS 55 bothersome symptom 55 triiodothyronine 55 Hippocampal 55 inotropic 55 gastroduodenal 55 ventricular repolarization 55 Naive Patients 55 imiquimod cream 55 Female Sexual Function 55 echocardiographic parameters 55 headache nasopharyngitis 55 biochemical relapse 55 ug kg 55 Interferon Alfa 55 somatic symptoms 55 Medication Adherence 55 spirometric 55 MetS 55 Subgroup Analysis 55 doxazosin 55 Novel Inhibitor 55 postural sway 55 Degenerative Disc Disease 55 Free Survival PFS 55 transaminases 55 Randomized Evaluation 55 Radiographic 55 hyperlipidaemia 55 ACR# [002] 55 Paroxysmal 55 Iron Deficiency 55 lactate dehydrogenase LDH 55 MSLT 55 adenoma recurrence 55 Coronary Artery Bypass Graft 55 Physical Component 55 serum lipid levels 55 Advanced Renal Cell 55 vitreous haze 55 Chronic Obstructive Lung 55 claudication 55 Abbott HUMIRA 55 constipation nausea 55 adrenocortical 55 intratympanic 55 Neuropsychiatric Inventory 55 Iron Deficiency Anemia 55 ALA PDT 55 #F FDG 55 Nilotinib 55 LPS induced 55 carotid artery intima media 55 Hyperlipidemia 55 Infarct 55 Nonspecific 55 electrophysiologic 55 Insulin Therapy 55 HSCT 55 concomitant medications 55 polyarticular 55 Index CDAI score 55 virological response 55 AUA Symptom Score 55 polyuria 55 artery stenosis 55 ropivacaine 55 Evaluable 55 PSA nadir 55 fatty infiltration 55 Numeric Rating Scale 55 Immunohistochemical 55 hip femoral neck 55 Exacerbation 55 Hypertensive Patients 55 PEGylated Fab fragment 55 Levels Linked 55 overactive bladder symptoms 55 Muscle Pain 55 mmol l 55 Slow Progression 55 troponin T 55 epoetin alpha 55 Diabetic Neuropathy 55 Relapsed Refractory 55 symptomatic VTE 55 Erectile 55 seropositivity 55 glycosylated hemoglobin levels 55 Hypotension 55 Hamilton Anxiety Scale 55 Nonsurgical 55 primary aldosteronism 55 T1a 55 Preoperatively 55 pharmacodynamic PD 55 Fatty Liver 55 Insulin sensitivity 55 TURBT 55 Shows Efficacy 55 Postherpetic Neuralgia 55 specific alkaline phosphatase 55 Endothelial 55 confidence intervals CIs 55 FFNS 55 sulfasalazine 55 atherosclerotic renal artery stenosis 55 Often Misdiagnosed 55 histologic 55 vWF 55 Modulates 55 Menstrual Pain 55 Combo Therapy 55 HeFH 55 TPV r 55 = #.#-#.# 55 interrater reliability 55 TNSS 55 progression TTP 55 Fibromyalgia Pain 55 Severity Scale 55 brachial artery flow 55 Microalbuminuria 55 ALSFRS R 55 ANCA associated 55 Seattle Angina Questionnaire 55 corrected QT interval 55 Efficacy Trial 55 Pathologic 55 symptomatic intracranial hemorrhage 55 Adiposity 55 HBeAg seroconversion 55 Solid Tumours 55 p = .# [001] 55 interleukin IL -# 55 Androgen 55 truncal 55 systolic function 55 improves glycemic 55 plasminogen activator inhibitor 55 hemoglobin A1c HbA1c 55 urine albumin 55 Axillary 55 Reduces Pain 55 #mg QD [002] 55 Lesion 55 Neoplasms 55 doxorubicin cyclophosphamide 55 Statistically Significant 55 MBq 55 Fasting plasma glucose 55 symptomatic intracranial 55 iliopsoas 55 diabetes mellitus DM 55 Soft Tissue Sarcoma 55 Clinician Administered PTSD 55 Liver Injury 55 nadolol 55 Hb A1C 55 endoscopic remission 55 ritonavir boosted 55 Preoperative 55 plasma lipids 55 μmol L 55 aPTT 55 arteriolar 55 soleus 55 Sexual Desire 55 Septic Shock 55 sUA 55 #mg BID [001] 55 fibrin deposition 55 undetectable HBV DNA 55 neurologic impairment 55 ibandronate 55 gait disturbances 55 Cockcroft Gault 55 Neuroprotective Effects 55 Cardiac Troponin 55 reflux disease GERD 55 colorectal carcinoma 54 Adenomas 54 Pediatric Patients 54 abdominal distension 54 Vertebral 54 #OHD 54 diaphoresis 54 lesional 54 Diabetic Foot Ulcers 54 clinicopathological features 54 STN stimulation 54 mIU ml 54 inducible nitric oxide synthase 54 ERalpha 54 point Likert scale 54 μg kg 54 Adrenal 54 immunoreactivity 54 Anxiety Depression 54 posttransplant 54 Antiviral Therapy 54 IgG antibody 54 Key secondary endpoints 54 juvenile idiopathic arthritis 54 MYCAMINE 54 serum aminotransferase levels 54 Systemic Lupus Erythematosus SLE 54 interquartile range IQR 54 neovascular 54 RoACTEMRA 54 CR CRu 54 percutaneous vertebroplasty 54 BPH benign prostatic 54 Fewer Side Effects 54 serum phosphorous 54 HAM D 54 Disord 54 INCB# [003] 54 specific antigen PSA 54 receiving XGEVA 54 Myocardial Infarction TIMI 54 oral antidiabetic medication 54 Topical Cream 54 glatiramer acetate 54 Strongly Linked 54 serum ALT 54 cortical atrophy 54 Fungal Infections 54 Hormone Levels 54 reflux symptoms 54 SLEDAI 54 intravitreal injections 54 neurocognitive function 54 QD dosing 54 Eur J Endocrinol 54 CONTRAINDICATIONS 54 Critically Ill Patients 54 antitrypsin 54 Dehydrogenase 54 Spinal Fluid 54 fasting insulin 54 Diastolic 54 Urinary 54 Leydig cell 54 Subscale 54 Oropharyngeal Candidiasis 54 Thrombus 54 NMES 54 colesevelam 54 pentoxifylline 54 histologically confirmed 54 Primary Endpoint 54 receiving VICTRELIS 54 Hemoglobin A1c 54 p = #.# [003] 54 intraobserver 54 FOLPI 54 Node Negative 54 FluCAM arm 54 Adjuvant Therapy 54 OAB symptoms 54 hemoglobin A1c levels 54 LDL Cholesterol 54 Sonographic 54 #.#/#.# mmHg [001] 54 apnea hypopnea index 54 Monotherapy 54 mild renal insufficiency 54 Cortical 54 Cerebrospinal Fluid 54 Hypertrophic 54 Gene Mutation Linked 54 QRS duration 54 receiving golimumab 54 BENICAR HCT 54 Endarterectomy 54 histopathological 54 airway hyper responsiveness 54 mean ± SEM 54 postdose 54 cognitive affective 54 cystic fibrosis chronic pancreatitis 54 secondary efficacy endpoint 54 Intrathecal 54 Antiangiogenic 54 cerebral oxygen saturation 54 carotid IMT 54 Chemoradiation 54 alicaforsen enema 54 LUTS 54 sensory neuropathy 54 #.#mg/dL 54 Hepatotoxicity 54 Geriatric Depression 54 serum PSA 54 patellofemoral 54 mL/min/#.# m2 54 Ventricular Tachycardia 54 Myocardial Perfusion 54 CSBMs 54 adenomatous 54 Adefovir 54 Acute Renal Failure 54 mg qd 54 comparator arm 54 antral 54 vasodilatation 54 serum triglycerides 54 Systemic Lupus Erythematosus 54 Magnetic Stimulation 54 Adjunctive Therapy 54 RECIST criteria 54 microbiological eradication 54 Iron Overload 54 HPA axis suppression 54 metastatic neuroendocrine tumors 54 ara C 54 expiratory 54 GOUT 54 bortezomib refractory 54 Placebo Controlled Study 54 HCV Genotype 54 Intracranial 54 Heart Rate Variability 54 State Examination MMSE 54 capillary density 54 #ß 54 APTIVUS R 54 left ventricular systolic 54 phosphorylated tau 54 Genetic Markers